A new polymyxin antibiotic targeting Gram-negative 'superbug' infections, developed by scientists at the Monash Institute of Pharmaceutical Sciences and the Monash Biomedicine Discovery Institute
/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.
